logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10815217 B1

PDFFull Text
Date of Patent:
Oct. 27, 2020

Filed:

Jul. 11, 2018

Inhibitor of p38 map kinase

Applicant:

Respivert Ltd, High Wycombe, GB;

Inventors:

Alistair Ian Longshaw, Nottingham, GB;

Euan Alexander Fraser Fordyce, Nottingham, GB;

Stuart Thomas Onions, Nottingham, GB;

John King-Underwood, Pendock, GB;

Jennifer Venable, Solana Beach, CA (US);

Assignee:

Respivert Ltd., High Wycombe, GB;

Attorney:

Hogan Lovells US LLP

Primary Examiner:

Brian E McDowell

Int. Cl.
CPC ...
A61K 31/497 (2006.01); C07D 401/14 (2006.01); A61K 31/4427 (2006.01); C07D 409/14 (2006.01); C07D 401/12 (2006.01); A61K 31/498 (2006.01); A61K 31/5377 (2006.01); A61K 31/541 (2006.01); A61K 31/551 (2006.01); C07D 413/14 (2006.01); C07D 487/04 (2006.01); A61K 9/00 (2006.01); A61K 47/26 (2006.01);
U.S. Cl.
CPC ...
C07D 401/14 (2013.01); A61K 9/0075 (2013.01); A61K 31/4427 (2013.01); A61K 31/497 (2013.01); A61K 31/498 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); A61K 31/551 (2013.01); A61K 47/26 (2013.01); C07D 401/12 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 487/04 (2013.01);
Abstract

A dry powder pharmaceutical formulation for inhalation including a compound of formula (I): that is 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof; and lactose as a topically acceptable diluent. An inhaler device containing the dry powder pharmaceutical formulation is also described.

Find Patent Forward Citations

Loading…